At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer
In Brief
A Phase 2 clinical trial evaluating Counseling, Psilocybin, and 1 other intervention for Hematopoietic and Lymphatic System Neoplasm and Metastatic Malignant Solid Neoplasm. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment of anxiety and depression in patients with cancer. In this study, the psilocybin being used is derived from the mushroom psilocybe cubensis using a patented process that results in a pharmaceutical grade version of psilocybin. Psilocybin acts by activating serotonin receptors on brain cells which can change perceptions and patterns of thinking in ways that may decrease anxiety.
Study Details
Timeline
Interventions
Participate in therapy visits
Given PO
Ancillary studies